These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568 [TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal acute graft-versus-host disease in children: histology for diagnosis, mesenchymal stromal cells for treatment, and biomarkers for prediction of response. Calkoen FG; Jol-van der Zijde CM; Mearin ML; Schweizer JJ; Jansen-Hoogendijk AM; Roelofs H; van Halteren AG; Egeler RM; van Tol MJ; Ball LM Biol Blood Marrow Transplant; 2013 Nov; 19(11):1590-9. PubMed ID: 23994245 [TBL] [Abstract][Full Text] [Related]
4. Pitfalls in the design of clinical trials for prevention or treatment of acute graft-versus-host disease. Martin PJ; Nash RA Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):31-6. PubMed ID: 16399599 [TBL] [Abstract][Full Text] [Related]
6. Use of mesenchymal stem cells as treatment for graft-versus-host disease: current knowledge and controversies. Ortín M; Sierra J Immunotherapy; 2011 Jun; 3(6):701-4. PubMed ID: 21668303 [No Abstract] [Full Text] [Related]
7. The mesenchymal stromal cells dilemma--does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road? Galipeau J Cytotherapy; 2013 Jan; 15(1):2-8. PubMed ID: 23260081 [TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring. Dander E; Lucchini G; Vinci P; Introna M; Masciocchi F; Perseghin P; Balduzzi A; Bonanomi S; Longoni D; Gaipa G; Belotti D; Parma M; Algarotti A; Capelli C; Golay J; Rovelli A; Rambaldi A; Biondi A; Biagi E; D'Amico G Leukemia; 2012 Jul; 26(7):1681-4. PubMed ID: 22289986 [No Abstract] [Full Text] [Related]
12. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. Ball LM; Bernardo ME; Roelofs H; van Tol MJ; Contoli B; Zwaginga JJ; Avanzini MA; Conforti A; Bertaina A; Giorgiani G; Jol-van der Zijde CM; Zecca M; Le Blanc K; Frassoni F; Egeler RM; Fibbe WE; Lankester AC; Locatelli F Br J Haematol; 2013 Nov; 163(4):501-9. PubMed ID: 23992039 [TBL] [Abstract][Full Text] [Related]
13. In vitro simulation of corneal epithelium microenvironment induces a corneal epithelial-like cell phenotype from human adipose tissue mesenchymal stem cells. Nieto-Miguel T; Galindo S; Reinoso R; Corell A; Martino M; Pérez-Simón JA; Calonge M Curr Eye Res; 2013 Sep; 38(9):933-44. PubMed ID: 23767776 [TBL] [Abstract][Full Text] [Related]
14. Mesenchymal stem cells as cellular immunosuppressants. Wolf D; Wolf AM Lancet; 2008 May; 371(9624):1553-4. PubMed ID: 18468526 [No Abstract] [Full Text] [Related]
15. Mesenchymal stem cells enhance the induction of mixed chimerism and tolerance to rat hind-limb allografts after bone marrow transplantation. Pan H; Zhao K; Wang L; Zheng Y; Zhang G; Mai H; Han Y; Yang L; Guo S J Surg Res; 2010 May; 160(2):315-24. PubMed ID: 19524257 [TBL] [Abstract][Full Text] [Related]
17. A role for mesenchymal stem cells in the control of graft-versus-host disease. Cohen JL; Sudres M Transplantation; 2009 May; 87(9 Suppl):S53-4. PubMed ID: 19424007 [TBL] [Abstract][Full Text] [Related]
19. [Problematic issues in clinical trials of mesenchymal stem cells and unraveling strategies]. Zhang WW; Guo ZK Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Aug; 15(4):901-4. PubMed ID: 17708830 [TBL] [Abstract][Full Text] [Related]
20. Remestemcel-L, the first cellular therapy product for the treatment of graft-versus-host disease. Daly A Drugs Today (Barc); 2012 Dec; 48(12):773-83. PubMed ID: 23243634 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]